Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
Joshua A TobinShivang JoshiJanet H FordRussell M NicholsShonda A FosterDustin RuffHolland C DetkeSheena K AuroraPublished in: Journal of medical economics (2022)
Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU.
Keyphrases
- double blind
- open label
- placebo controlled
- phase iii
- liver failure
- clinical trial
- healthcare
- phase ii
- respiratory failure
- study protocol
- aortic dissection
- drug induced
- phase ii study
- hepatitis b virus
- radiation therapy
- squamous cell carcinoma
- randomized controlled trial
- emergency department
- extracorporeal membrane oxygenation
- intensive care unit
- health information
- mechanical ventilation